KR102243243B1 - 신규한 cho 통합 부위 및 이의 용도 - Google Patents
신규한 cho 통합 부위 및 이의 용도 Download PDFInfo
- Publication number
- KR102243243B1 KR102243243B1 KR1020177012465A KR20177012465A KR102243243B1 KR 102243243 B1 KR102243243 B1 KR 102243243B1 KR 1020177012465 A KR1020177012465 A KR 1020177012465A KR 20177012465 A KR20177012465 A KR 20177012465A KR 102243243 B1 KR102243243 B1 KR 102243243B1
- Authority
- KR
- South Korea
- Prior art keywords
- site
- exogenous
- goi
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000010354 integration Effects 0.000 title claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 151
- 230000014509 gene expression Effects 0.000 claims abstract description 80
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 77
- 239000013598 vector Substances 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims description 139
- 150000007523 nucleic acids Chemical group 0.000 claims description 119
- 239000012634 fragment Substances 0.000 claims description 94
- 239000002773 nucleotide Substances 0.000 claims description 84
- 125000003729 nucleotide group Chemical group 0.000 claims description 83
- 108010091086 Recombinases Proteins 0.000 claims description 64
- 102000018120 Recombinases Human genes 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 29
- 239000003550 marker Substances 0.000 claims description 29
- 230000006798 recombination Effects 0.000 claims description 28
- 238000005215 recombination Methods 0.000 claims description 28
- 108020004999 messenger RNA Proteins 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 101710163270 Nuclease Proteins 0.000 claims description 21
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 8
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 239000000539 dimer Substances 0.000 claims description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 108090000992 Transferases Proteins 0.000 claims description 3
- 102000004357 Transferases Human genes 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 108010074506 Transfer Factor Proteins 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 13
- 210000003527 eukaryotic cell Anatomy 0.000 abstract description 11
- 230000002759 chromosomal effect Effects 0.000 abstract description 5
- 230000010473 stable expression Effects 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 35
- 108091033319 polynucleotide Proteins 0.000 description 21
- 102000040430 polynucleotide Human genes 0.000 description 21
- 239000002157 polynucleotide Substances 0.000 description 21
- 230000037431 insertion Effects 0.000 description 18
- 238000003780 insertion Methods 0.000 description 18
- 239000013604 expression vector Substances 0.000 description 16
- 230000001404 mediated effect Effects 0.000 description 14
- 230000008685 targeting Effects 0.000 description 13
- 238000002744 homologous recombination Methods 0.000 description 12
- 230000006801 homologous recombination Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 108010054624 red fluorescent protein Proteins 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 241000699802 Cricetulus griseus Species 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 230000010076 replication Effects 0.000 description 8
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000010363 gene targeting Methods 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 108010051219 Cre recombinase Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 5
- 108091092724 Noncoding DNA Proteins 0.000 description 5
- 108010052160 Site-specific recombinase Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 108010082025 cyan fluorescent protein Proteins 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 108010045262 enhanced cyan fluorescent protein Proteins 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000003151 transfection method Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241000006867 Discosoma Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- -1 GOI) Chemical class 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 101150062015 hyg gene Proteins 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 101100256223 Caenorhabditis elegans cho-1 gene Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 102100027377 HBS1-like protein Human genes 0.000 description 1
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 238000011965 cell line development Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067774P | 2014-10-23 | 2014-10-23 | |
| US62/067,774 | 2014-10-23 | ||
| PCT/US2015/056653 WO2016064999A1 (en) | 2014-10-23 | 2015-10-21 | Novel cho integration sites and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170096999A KR20170096999A (ko) | 2017-08-25 |
| KR102243243B1 true KR102243243B1 (ko) | 2021-04-22 |
Family
ID=54602002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177012465A Active KR102243243B1 (ko) | 2014-10-23 | 2015-10-21 | 신규한 cho 통합 부위 및 이의 용도 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9816110B2 (enExample) |
| EP (1) | EP3209785B1 (enExample) |
| JP (1) | JP6668340B2 (enExample) |
| KR (1) | KR102243243B1 (enExample) |
| CN (1) | CN107109434A (enExample) |
| AR (1) | AR102420A1 (enExample) |
| AU (1) | AU2015335921B2 (enExample) |
| BR (1) | BR112017008022A2 (enExample) |
| CA (1) | CA2965495C (enExample) |
| EA (1) | EA037255B1 (enExample) |
| IL (1) | IL251674B (enExample) |
| MX (1) | MX2017005306A (enExample) |
| MY (1) | MY184103A (enExample) |
| SG (1) | SG11201703149RA (enExample) |
| TW (2) | TWI747808B (enExample) |
| WO (1) | WO2016064999A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3209785B1 (en) | 2014-10-23 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Novel cho integration sites and uses thereof |
| US10329594B1 (en) | 2015-09-03 | 2019-06-25 | CHO Plus, Inc. | Cell lines for high level production of protein-based pharmaceuticals |
| US11649449B2 (en) | 2015-09-03 | 2023-05-16 | CHO Plus, Inc. | Hybrid cell lines for high level production of a target protein |
| US11512144B2 (en) | 2016-04-20 | 2022-11-29 | Regeneran Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing loci |
| IL262268B2 (en) * | 2016-04-20 | 2024-05-01 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| EP3559236A4 (en) * | 2016-12-20 | 2020-11-04 | Development Center for Biotechnology | TARGETED INTEGRATION SITES IN THE CHINESE HAMSTER OVARIAN CELL GENOME |
| US20210309988A1 (en) * | 2017-02-07 | 2021-10-07 | Sigma-Aldrich Co. Llc | Stable targeted integration |
| EP3583205A1 (en) * | 2017-02-17 | 2019-12-25 | Lonza Ltd | Mammalian cells for producing adeno-associated viruses |
| EP3601542A4 (en) * | 2017-03-19 | 2021-01-13 | Applied Stemcell, Inc. | NEW INTEGRATION SITES AND THEIR USES |
| JP7087061B2 (ja) * | 2017-08-11 | 2022-06-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｈｏ細胞内の組込み部位 |
| CN107723276B (zh) * | 2017-11-02 | 2021-08-13 | 上海交通大学 | 一种稳定高表达目标产物的细胞株的构建方法和试剂盒 |
| CN111566208A (zh) * | 2017-12-22 | 2020-08-21 | 生物辐射实验室股份有限公司 | 利用CRISPR/Cas基因靶向控制生物体表型 |
| TW201932600A (zh) * | 2017-12-22 | 2019-08-16 | 美商建南德克公司 | 核酸之靶向整合 |
| CN109321604B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用 |
| CN109337927B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用 |
| CN109295092B (zh) * | 2018-10-30 | 2021-06-29 | 江南大学 | 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用 |
| CN109295093B (zh) * | 2018-10-30 | 2021-08-03 | 江南大学 | 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用 |
| CN109207432B (zh) * | 2018-10-30 | 2021-08-03 | 江南大学 | 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用 |
| CN109136193B (zh) * | 2018-10-30 | 2021-07-06 | 江南大学 | 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用 |
| KR20210107057A (ko) * | 2018-12-21 | 2021-08-31 | 제넨테크, 인크. | 핵산의 표적화 통합 |
| IL286630B2 (en) * | 2019-04-02 | 2025-05-01 | Chugai Pharmaceutical Co Ltd | Method for introducing a target-specific foreign gene |
| CN114080454A (zh) | 2019-06-26 | 2022-02-22 | 豪夫迈·罗氏有限公司 | 核酸的随机化构型靶向整合 |
| EP3901266A1 (en) * | 2020-04-22 | 2021-10-27 | LEK Pharmaceuticals d.d. | Super-enhancers for recombinant gene expression in cho cells |
| EP4158041A4 (en) * | 2020-06-02 | 2024-09-25 | Catalent Pharma Solutions, LLC | CELL LINES WITH MULTIPLE DOCKING ZONES FOR GENE INSERTION |
| TW202216991A (zh) * | 2020-06-24 | 2022-05-01 | 美商建南德克公司 | 核酸之靶向整合 |
| IL302046A (en) | 2020-10-15 | 2023-06-01 | Hoffmann La Roche | Nucleic acid structures for va RNA transcription |
| CN113755447B (zh) * | 2021-09-23 | 2022-04-29 | 云舟生物科技(广州)股份有限公司 | 一种用于生产腺病毒的293a细胞株及其制备与应用 |
| KR20240099242A (ko) | 2021-10-18 | 2024-06-28 | 리제너론 파마슈티칼스 인코포레이티드 | 안정적인 통합 부위를 생산하기 위한 통합된 cas9 유전자를 포함하는 포유동물 세포, 및 안정적인 통합 부위 및 기타 부위를 포함하는 포유동물 세포 |
| MX2024004647A (es) | 2021-10-18 | 2024-05-02 | Regeneron Pharma | Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. |
| KR20240101596A (ko) | 2021-10-18 | 2024-07-02 | 리제너론 파마슈티칼스 인코포레이티드 | 폴리뉴클레오티드의 제어된 전사 |
| WO2023147462A2 (en) * | 2022-01-28 | 2023-08-03 | The Trustees Of Columbia University In The City Of New York | Genetic modifications for xenotransplantation |
| CN117305334B (zh) * | 2022-06-21 | 2024-11-08 | 深圳太力生物技术有限责任公司 | 靶向整合细胞及其制备方法、生产目标基因表达产物的方法 |
| WO2024107451A1 (en) | 2022-11-18 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Methods for detecting and evaluating viruses and virus-like particles |
| CN118726475B (zh) * | 2023-03-28 | 2025-07-08 | 深圳太力生物技术有限责任公司 | 核酸、重组载体、靶向整合细胞、基因表达方法和应用 |
| WO2024211287A1 (en) * | 2023-04-03 | 2024-10-10 | Seagen Inc. | Production cell lines with targeted integration sites |
| TW202528546A (zh) | 2023-09-07 | 2025-07-16 | 美商再生元醫藥公司 | 經共價表面修飾之腺相關病毒的生產及純化 |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| ATE539161T1 (de) | 1998-07-21 | 2012-01-15 | Millipore Corp | Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid |
| US6521419B1 (en) * | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| AU2002254529A1 (en) | 2001-04-04 | 2002-10-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Nucleic acids for transgene expression |
| US20040045043A1 (en) * | 2002-05-20 | 2004-03-04 | Finney Robert E. | Compositions and methods for generating conditional knockouts |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| ES2627552T3 (es) * | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
| CN105969807A (zh) * | 2011-04-05 | 2016-09-28 | 斯克利普斯研究所 | 染色体着陆垫及相关用途 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP3683319A1 (en) * | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| CA2852955C (en) * | 2011-10-27 | 2021-02-16 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| CA2871524C (en) | 2012-05-07 | 2021-07-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| EP3209785B1 (en) | 2014-10-23 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Novel cho integration sites and uses thereof |
-
2015
- 2015-10-21 EP EP15797495.7A patent/EP3209785B1/en active Active
- 2015-10-21 EA EA201790698A patent/EA037255B1/ru unknown
- 2015-10-21 WO PCT/US2015/056653 patent/WO2016064999A1/en not_active Ceased
- 2015-10-21 CN CN201580069889.1A patent/CN107109434A/zh active Pending
- 2015-10-21 JP JP2017519646A patent/JP6668340B2/ja active Active
- 2015-10-21 BR BR112017008022-2A patent/BR112017008022A2/pt not_active Application Discontinuation
- 2015-10-21 MY MYPI2017701254A patent/MY184103A/en unknown
- 2015-10-21 CA CA2965495A patent/CA2965495C/en active Active
- 2015-10-21 SG SG11201703149RA patent/SG11201703149RA/en unknown
- 2015-10-21 US US14/919,300 patent/US9816110B2/en active Active
- 2015-10-21 AU AU2015335921A patent/AU2015335921B2/en active Active
- 2015-10-21 KR KR1020177012465A patent/KR102243243B1/ko active Active
- 2015-10-21 MX MX2017005306A patent/MX2017005306A/es unknown
- 2015-10-22 TW TW104134716A patent/TWI747808B/zh active
- 2015-10-22 TW TW110128495A patent/TWI780847B/zh active
- 2015-10-23 AR ARP150103445A patent/AR102420A1/es unknown
-
2017
- 2017-04-09 IL IL251674A patent/IL251674B/en active IP Right Grant
- 2017-10-13 US US15/783,525 patent/US20180030480A1/en not_active Abandoned
-
2019
- 2019-09-19 US US16/575,506 patent/US11788102B2/en active Active
-
2021
- 2021-02-12 US US17/175,025 patent/US11268109B2/en active Active
-
2023
- 2023-09-06 US US18/461,798 patent/US20240018553A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
Non-Patent Citations (3)
| Title |
|---|
| Cytotechnology.,51(3):171-182(2006.11.15.) |
| Nat Biotechnol.,29(8):735-741(2011.7.31.) |
| Nat Biotechnol.,31(8):759-765(2013.6.21.) |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170096999A (ko) | 2017-08-25 |
| TWI747808B (zh) | 2021-12-01 |
| EP3209785B1 (en) | 2019-07-31 |
| EP3209785A1 (en) | 2017-08-30 |
| AU2015335921A1 (en) | 2017-05-04 |
| TW202144576A (zh) | 2021-12-01 |
| SG11201703149RA (en) | 2018-02-27 |
| JP6668340B2 (ja) | 2020-03-18 |
| CA2965495C (en) | 2022-05-24 |
| US20160115502A1 (en) | 2016-04-28 |
| MY184103A (en) | 2021-03-18 |
| US11268109B2 (en) | 2022-03-08 |
| CA2965495A1 (en) | 2016-04-28 |
| US20180030480A1 (en) | 2018-02-01 |
| EA037255B1 (ru) | 2021-02-26 |
| US20210171984A1 (en) | 2021-06-10 |
| US20240018553A1 (en) | 2024-01-18 |
| CN107109434A (zh) | 2017-08-29 |
| US9816110B2 (en) | 2017-11-14 |
| TW201629229A (zh) | 2016-08-16 |
| WO2016064999A1 (en) | 2016-04-28 |
| IL251674A0 (en) | 2017-06-29 |
| AU2015335921B2 (en) | 2020-06-25 |
| EA201790698A1 (ru) | 2018-01-31 |
| MX2017005306A (es) | 2018-01-09 |
| TWI780847B (zh) | 2022-10-11 |
| US20200002732A1 (en) | 2020-01-02 |
| JP2017535258A (ja) | 2017-11-30 |
| BR112017008022A2 (pt) | 2018-02-20 |
| IL251674B (en) | 2020-10-29 |
| US11788102B2 (en) | 2023-10-17 |
| AR102420A1 (es) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102243243B1 (ko) | 신규한 cho 통합 부위 및 이의 용도 | |
| US12214054B2 (en) | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use | |
| CN106893739A (zh) | 用于靶向基因操作的新方法和系统 | |
| CN114667344A (zh) | 具有增强的dna产生的经修饰的细菌逆转录元件 | |
| JP2021512617A (ja) | ＣｏｒｙｎｅｂａｃｔｅｒｉｕｍにおいてＣＲＩＳＰＲを使用するゲノム編集 | |
| JP2019503653A (ja) | トランスポゾン系、それを含むキット及びそれらの使用 | |
| CN115552002A (zh) | 基因组改造方法及基因组改造试剂盒 | |
| EP1815001B1 (en) | Gene trap cassettes for random and targeted conditional gene inactivation | |
| Li et al. | Versatile and efficient mammalian genome editing with Type IC CRISPR System of Desulfovibrio vulgaris | |
| JP7109009B2 (ja) | 遺伝子ノックアウト方法 | |
| EP4612306A2 (en) | A screening method | |
| TWI704224B (zh) | 編輯核酸序列之組成物及方法 | |
| EP4506455A1 (en) | Cell suitable for gene engineering, cell engineering and cellular medicine, and method for producing same | |
| HK1235432B (en) | Novel cho integration sites and uses thereof | |
| HK1235432A1 (en) | Novel cho integration sites and uses thereof | |
| JP2007124915A (ja) | リコンビニアリングコンストラクト、及びジーンターゲティングコンストラクト作製用ベクター | |
| CN117597439A (zh) | Ciita靶向锌指核酸酶 | |
| HK40096853A (zh) | Regnase-1和/或tgfbrii被破坏的基因工程化t细胞具有改善的功能性和持久性 | |
| da Fonseca Lopes | Easy Embryonicstem Cell: A new Tool to Manipulate Gene Expression in Embryoid Bodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170508 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201016 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20201016 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201023 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210201 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210416 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210419 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240401 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250324 Start annual number: 5 End annual number: 5 |